


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-34 (canceled)


Claim 35 (currently amended): A process for the preparation of epothilone derivatives of formula 9:



R1 is methyl;

R2 is an unsubstituted or substituted aryl; an unsubstituted or substituted heteroaryl; or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus;  
comprising the steps of:

a) reacting a compound of formula 1:



(1)


wherein R<sup>2</sup> has the meanings given above; wherein a mesylate group of the compound of  
formula 1 may be replaced with a tosylate group; and  $\textcircled{\text{P}}$  is an alcohol protecting group;  
 with a compound of formula 2:




(3)

P


- 3 -




(4)

wherein R<sub>2</sub> and  have the meanings given above and wherein a mesylate group of the compound of formula 4 may be replaced with a tosylate group;


c) converting the compound of formula 4 to produce a compound of formula 5:



(5)


wherein R<sub>2</sub> and  have the meanings given above and wherein the mesylate group of the compound of formula 5 may be replaced with a tosylate group;

d) reacting compounds of above formula 5 with a reducing reagent in an inert solvent to yield a compound of formula 6:




(6)  
wherein R<sub>2</sub> and the (P) above have given meanings;

e) hydrolysing the compound of formula 6, to produce a compound of formula 7:



(7)  
wherein R<sub>2</sub> and (P) have the above given meanings;

f) macrolactonizing a compound of formula 7, to produce the epothilone derivative of formula 8:



(8)

wherein R<sup>2</sup> and <sup>P</sup> have the above defined meanings; and

g) treating the compound of formula 8 with HF·pyridine in an inert solvent to produce the epothilone derivatives of formula 9.

Claim 36 (previously presented): The process according to claim 35, wherein in step a) the compound of formula 1 is reacted with the compound of formula 2 in the presence of TiCl<sub>4</sub> and Hünig base (iPr<sub>2</sub>Net) in dichloromethane.

Claim 37 (previously presented): The process according to claim 35, wherein in step b) the compound of formula 3 is reacted with a silyl-ether forming compound in the presence of 2,6-lutidine in dichloromethane.

Claim 38 (previously presented): The process according to claim 35, wherein in step c) the compound of formula 4 is converted by splitting off the chiral auxiliary group with TBAOH/H<sub>2</sub>O<sub>2</sub> in DME or LiO<sub>2</sub>H in THF/MeOH/H<sub>2</sub>O.

Claim 39 (previously presented): The process according to claim 35, wherein in step d) the compound of formula 5 is reacted with LiBHET<sub>3</sub> in THF.

Claim 40 (previously presented): The process according to claim 35, wherein in step e) the compound of formula 6 is hydrolysed with TASF or HF pyridine in an inert solvent.

Claim 41 (previously presented): The process according to claim 35, wherein in step f) the compound of formula 7 is macrolactonized by treating with Et<sub>3</sub>N and 2,4,6-trichlorobenzoyl chloride and subsequently reacted with a solution of 4-DMAP in toluene.

Claims 42-68 (canceled)

Claim 69 (currently amended): The process according to claim 35 wherein a mesylate group of the compound of formula 1 ~~may be~~ is not replaced with a tosylate group.

Claim 70 (previously presented): The process according to claim 35 where step a) first occurs at lower temperatures between -50° to -100°C and thereafter elevated to temperatures between -20° to +20°C to obtain the compound of formula 3.

Claim 71 (previously presented): The process according to claim 35 wherein step b) occurs at temperature between -70° and 25°C.

Claim 72 (previously presented): The process according to claim 35 wherein step e) the compound of formula 6 is hydrolyzed with a desilylation reagent or an acid in an inert solvent.

Claim 73 (previously presented): The process according to claim 72 wherein the acid in an inert solvent is TASF in THF or HF-pyridine in THF.

Claim 74 (previously presented): The process according to claim 35 where step a) occurs at a temperature between 0°C and 30°C.